Payment overview · 2025
General Payments
$664.20
36 reported records · 14 companies
Healthcare provider profile · identity verified
Perry Wayne Sexton, MD
Allopathic & Osteopathic Physicians|Family Medicine · ENCINITAS, CA · NPI 1972665339
Verified facts
What the public records show
CMS Open Payments records show Perry Wayne Sexton, MD received $664.20 in general payments during 2025 across 36 reported records.
Indivior Inc. accounted for 33.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Indivior Inc. | Unresolved — no canonical attribution shown | $225.34 | 33.9% | 15 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $107.23 | 16.1% | 6 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $45.44 | 6.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $44.89 | 6.8% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $36.94 | 5.6% | 2 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $31.25 | 4.7% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $29.62 | 4.5% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $28.41 | 4.3% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $25.56 | 3.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.96 | 3.2% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $19.18 | 2.9% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.16 | 2.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.66 | 2.5% | 1 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $15.56 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $664.20 | 36 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $225.34 | 15 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $57.63 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $49.60 | 3 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $45.44 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $44.89 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $44.89 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $44.17 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $36.94 | 2 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $31.25 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $29.62 | 1 | 2025 |
Source payment records
|
|||||
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $28.41 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $25.56 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $20.96 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $20.42 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $19.18 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.16 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.66 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.66 | 1 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $15.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 49 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 51 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
47 | 44 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 234 | 71 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 221 | 26 |
| Naproxen | Naproxen | 215 | 100 |
| Levothyroxine Sodium | Levothyroxine Sodium | 183 | 49 |
| Gabapentin | Gabapentin | 176 | 45 |
| Losartan Potassium | Losartan Potassium | 159 | 45 |
| Metformin Hcl | Metformin Hcl | 150 | 44 |
| Zolpidem Tartrate | Zolpidem Tartrate | 148 | 24 |
| Omeprazole | Omeprazole | 147 | 42 |
| Amlodipine Besylate | Amlodipine Besylate | 145 | 43 |
| Alprazolam | Alprazolam | 139 | 24 |
| Lisinopril | Lisinopril | 117 | 33 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 114 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 98 | 38 |
| Clonazepam | Clonazepam | 91 | 17 |
| Lorazepam | Lorazepam | 77 | 16 |
| Trazodone Hcl | Trazodone Hcl | 77 | 19 |
| Ibuprofen | Ibuprofen | 75 | 17 |
| Simvastatin | Simvastatin | 75 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 73 | 19 |
| Famotidine | Famotidine | 72 | 18 |
| Buprenorphine Hcl | Buprenorphine Hcl | 71 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 71 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 69 | 24 |
| Diazepam | Diazepam | 69 | 12 |
| Azithromycin | Azithromycin | 67 | 54 |
| Bupropion Xl | Bupropion Hcl | 67 | 25 |
| Pantoprazole Sodium | Pantoprazole Sodium | 66 | 24 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 63 | 43 |
| Alendronate Sodium | Alendronate Sodium | 62 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 62 | 15 |
| Atenolol | Atenolol | 59 | 14 |
| Metoprolol Succinate | Metoprolol Succinate | 59 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 56 | 35 |
| Rybelsus | Semaglutide | 51 | suppressed |
| Eliquis | Apixaban | 49 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 47 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 46 | 11 |
| Prednisone | Prednisone | 46 | 31 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 44 | 12 |
| Furosemide | Furosemide | 42 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 42 | suppressed |
| Celecoxib | Celecoxib | 41 | 14 |
| Benazepril Hcl | Benazepril Hcl | 38 | suppressed |
| Potassium Chloride | Potassium Chloride | 38 | suppressed |
| Ondansetron Odt | Ondansetron | 37 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | suppressed |
| Temazepam | Temazepam | 35 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 33 | 21 |
| Allopurinol | Allopurinol | 32 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 30 | 12 |
| Mirtazapine | Mirtazapine | 30 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 29 | 11 |
| Carvedilol | Carvedilol | 28 | suppressed |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 27 | suppressed |
| Lamotrigine | Lamotrigine | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 26 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 26 | suppressed |
| Baclofen | Baclofen | 25 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 23 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 23 | suppressed |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Fentanyl | Fentanyl | 20 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 20 | suppressed |
| Pregabalin | Pregabalin | 20 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Dextroamphetamine Sulfate | Dextroamphetamine Sulfate | 19 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 19 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 19 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 15 |
| Liothyronine Sodium | Liothyronine Sodium | 16 | suppressed |
| Movantik | Naloxegol Oxalate | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 13 |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | 12 |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Meloxicam | Meloxicam | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Testosterone | Testosterone | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Jardiance | Empagliflozin | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Sunosi | Solriamfetol Hcl | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $664.20 · 36 records | Indivior Inc. | AREXVY, BRIXADI, ELIQUIS, Flucelvax, General - Pain Management, Kerendia, LOREEV XR, MOUNJARO, Ozempic, QULIPTA, Rybelsus, SPRAVATO, SUBLOCADE, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, VIVITROL, VRAYLAR, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error